Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px
Document › Details

Riboxx GmbH. (2/4/16). "Press Release: Riboxx Pharmaceuticals and Tollys S.A.S Announce an Exclusive License Agreement for Treatment of Toll-like 3 Positive Cancers". Radebeul & Lyon.

Region Region ALL
Organisations Organisation Riboxx GmbH (Riboxx Pharmaceuticals)
  Organisation 2 Tollys S.A.S.
Products Product Apoxxim® TLR3-ligand
  Product 2 drug development
Index term Index term Tollys–Riboxx: cancer drug, 201602– license ww excl to Apoxxim TLR3-ligand programme to Tollys
Persons Person Rohayem, Jacques (Riboxx 201602 CEO + CSO)
  Person 2 Martin, Jacques-François (Parteurop Pharma 201602 President + Founder before Mymetics + Chiron Vaccines)
     


RIBOXX PHARMACEUTICALS, a biotech company developing Toll-like-receptor (TLR) and RIG-I-like-Receptor (RLR) ligands, and TOLLYS SAS, a biotech company developing new therapeutic strategies in cancer, today announced that they have signed a license agreement that grants TOLLYS exclusive global development and commercialization rights to a new drug development program, which RIBOXX will refer to as APOXXIM®. Under the terms of the license agreement, TOLLYS will assume sole responsibility for global development and commercialization of APOXXIM® product candidate. Riboxx will be responsible for manufacturing and supply of APOXXIM® to TOLLYS.

APOXXIM® is a Toll-like Receptor 3 (TLR3)-ligand that eliminates cancer cells by activating the TLR3 pathway. APOXXIM® displays unique physico-chemical and biological properties, as well as optimal biodisponibility with increased stability to degradation in body fluids such as human plasma. APOXXIM® is manufactured with the unique patented cGMP TENPORA®-Process of Riboxx.

Jacques Rohayem, CEO and CSO of RIBOXX PHARMACEUTICALS declared: "We are very thrilled to start this collaboration with TOLLYS, a company with a very strong scientific expertise in cancer therapy. This collaboration expands the portfolio of Riboxx drug development programs such as RIBOXXIM®, RIBOXXOL® and QUADROXXIM®, mainly focusing on cancer immunotherapy."

Jacques-François Martin, President of TOLLYS declared: "TOLLYS is very pleased to start this collaboration towards the development of a new and unique therapeutic strategy in cancer. The potential of TLR3-Ligands such as APOXXIM® to treat cancer has been extensively studied in the past decades by scientists at TOLLYS, with a particular focus on TLR3-positive cancers".


About RIBOXX PHARMACEUTICALS

RIBOXX PHARMACEUTICALS is a biotech company developing proprietary Toll-like-receptor (TLR) ligands and RIG-I-like-Receptor (RLR) ligands for applications in cancer immunotherapy. RIBOXX IP portfolio includes 17 PCT patent families so far, with 8 PCT patents granted in EU and/or Japan.


About TOLLYS SAS

TOLLYS SAS is a biotech company developing drugs targeting TLR3-positive cancer cells. TOLLYS SAS has a strong expertise in the design and development of anti-cancer strategies through activation of TLR3-pathway.


Contacts

Dr. Jacques ROHAYEM
CEO & CSO
RIBOXX PHARMACEUTICALS
Tel. 0049 351 8336010
business.development@riboxx.com
www.riboxx-pharma.com

Jacques-François MARTIN
President
TOLLYS SAS
Tel. 0033 4 78426389
jfmartin@parteurop.fr

   
Record changed: 2019-04-26

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x112px

More documents for Riboxx GmbH (Riboxx Pharmaceuticals)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px




» top